Rohto Pharmaceutical (4527)

Currency in JPY
2,486.5
-13.5(-0.54%)
Closed·

4527 Financial Summary

Key Ratios

P/E Ratio16.69
Price/Book2.12
Debt / Equity17.2%
Return on Equity12.75%
Dividend Yield1.65%
EBITDA51.61B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of JPY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 150.90%
Dividend Yield
1.65%
Industry Median 2.48%
Annualised payout
41.00
Paid unevenly
5-Years Growth
-
Growth Streak

Analyst Ratings

5 Buy
3 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2,606.7
(+4.83% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
52.09 / --
Revenue / Forecast
81.96B / 78.72B
EPS Revisions
Last 90 days

FAQ

What were Rohto Pharmaceutical's earnings for the latest quarter?

The Rohto Pharmaceutical EPS (TTM) is 150.90. Rohto Pharmaceutical reported sales of 81,964.00, net income of 11,769.00, and EPS of 52.09 for the latest quarter.

What was Rohto Pharmaceutical's net income for the latest quarter?

Rohto Pharmaceutical's net income for the latest quarter was 11,769.00.

How did Rohto Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 82,730.00 in the previous quarter to 81,964.00 in the latest quarter, and net income moved from 6,200.00 to 11,769.00 compared to the previous quarter.

What is Rohto Pharmaceutical's net profit margin on a TTM basis?

Rohto Pharmaceutical's trailing twelve months (TTM) net profit margin is 10.05%.

How does Rohto Pharmaceutical's debt to equity ratio compare to industry standards?

Rohto Pharmaceutical's total debt-to-equity ratio is 17.20%.

What is Rohto Pharmaceutical's return on investment on a TTM basis?

Rohto Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 12.75%.

What were Rohto Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Rohto Pharmaceutical reported total assets of 428,326.00 million and total liabilities of 84,839.00 million.

How has Rohto Pharmaceutical's total revenue grown this year?

Rohto Pharmaceutical's total revenue was 82,730.00 in the previous quarter and 81,964.00 in the latest quarter.

What is Rohto Pharmaceutical's gross margin on a TTM basis?

Rohto Pharmaceutical's trailing twelve months (TTM) gross margin is 56.39%.

What was Rohto Pharmaceutical's revenue per share for the latest quarter?

Rohto Pharmaceutical's revenue per share for the latest quarter was 1,940.88.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.